초록 ▼

Supplemented matrices comprising a PTH releasably incorporated therein, optionally containing a granular material, which are used to heal bone fractures, particularly bone fractures with a risk of becoming delayed unions or non-unions, are described herein. The PTH is incorporated either through cov

Supplemented matrices comprising a PTH releasably incorporated therein, optionally containing a granular material, which are used to heal bone fractures, particularly bone fractures with a risk of becoming delayed unions or non-unions, are described herein. The PTH is incorporated either through covalent linkage to the matrix or through non-covalent interaction with the matrix and/or the granules. These supplemented matrices decrease the time of healing compared to autograft and or trigger healing of bone fractures which otherwise would not heal. The matrices are biocompatible, preferably biodegradable, and can be formed in vitro or in vivo, at the time of implantation. The PTH may be a part of a fusion peptide. PTH can be incorporated into the matrices with full retention of its bioactivity. PTH can be releasably incorporated in the matrix.

대표청구항 ▼

1. A method of repairing a bone fracture, comprising administering to the site of the bone fracture, a formulation capable of forming a supplemented matrix under physiological conditions, wherein the bone fracture is a discontinuity in the bone structure which results in two or more distinct bone se

1. A method of repairing a bone fracture, comprising administering to the site of the bone fracture, a formulation capable of forming a supplemented matrix under physiological conditions, wherein the bone fracture is a discontinuity in the bone structure which results in two or more distinct bone segments of the fractured bone,and forming a supplemented matrix at the site,wherein the supplemented matrix comprises (i) PTH or a PTH fusion peptide(ii) a matrix material comprising fibrin,wherein the PTH or PTH fusion peptide is present in an effective amount to rejoin and realign the segments of the fractured bone. 2. The method of claim 1, wherein the supplemented matrix further comprises a granular material comprising a calcium mineral. 3. The method according to claim 1, wherein the bone fracture is a fracture of the distal radius, tibia, femur, fibula, radius, ulna, humerus, hip, or vertebra. 4. The method of claim 1, wherein the fracture is a long bone fracture. 5. The method of claim 1, wherein the PTH or PTH fusion peptide is present in a concentration range of between 0.01 and 2 mg/mL matrix. 6. The method of claim 1, wherein the supplemented matrix is administered by injecting a formulation capable of forming a fibrin matrix into the site of the bone fracture, wherein the formulation comprises(i) a peptide selected from the group consisting of PTH and a PTH fusion peptide;a fibrinogen precursor component; and(iii) a thrombin precursor component,wherein the PTH or PTH fusion peptide is present in a concentration range of between 0.01 to 2 mg/mL fibrin matrix or precursor components forming the matrix. 7. The method of claim 1, wherein the site is in a human. 8. The method of claim 6 wherein the fibrinogen precursor component or the thrombin precursor component further comprises a calcium ion source. 9. The method of claim 6, wherein the formulation further comprises a granular material comprising a calcium mineral. 10. The method of claim 1, wherein the PTH fusion peptide comprises at least two domains wherein the first domain comprises PTH and the second domain comprises a crosslinkable substrate domain. 11. The method of claim 1, wherein the PTH is selected from the group consisting of PTH1-84, PTH1-38, PTH1-34, PTH1-31 and PTH1-25. 12. The method of claim 11, wherein the PTH is PTH1-34. 13. The method of claim 10, wherein the second domain comprises a transglutaminase substrate domain. 14. The method of claim 13, wherein the transglutaminase domain comprises a Factor XIIIa substrate domain. 15. The method of claim 10, wherein PTH fusion peptide further comprises a degradation site between the first and the second domains. 16. The method of claim 2, wherein the granular material is a mixture of tricalcium phosphate and hydroxyapatite. 17. The method of claim 3, wherein the site is the tibia. 18. The method of claim 2, wherein the granular material is selected from the group consisting of hydroxyapatite, calcium phosphate and calcium sulphate and combinations thereof.